Peptide News Digest

CagriSema Hits 25% Weight Loss in Women, Senators Target 'Research Use Only' Retatrutide, Semaglutide Dosing

Novo reports 25% weight loss in women on CagriSema, senators press FDA on 'research use only' retatrutide, and high-dose semaglutide starts raise dropout.

6 stories · Covering clinical-trials, regulatory, research

Editor's Note

Tuesday mixed a company's best-case numbers with signs of strain around obesity drugs. Novo said women in its CagriSema trial lost 25% of their weight on average, above the 22.7% for the whole trial, but these were after-the-fact analyses presented at a menopause meeting weeks before an FDA decision expected this quarter. In Washington, Sen. Jim Banks led senators asking the FDA and Customs to shut down vendors who sell unapproved drugs such as retatrutide as 'research use only,' citing a 265% rise in poison-center reports involving illicit retatrutide. Two Diabetes, Obesity and Metabolism papers looked at everyday semaglutide use: starting at higher doses than recommended was tied to more early dropouts, and a pooled look at grip strength found no clear change, though the data were weak. In the lab, Singapore researchers built peptide droplets that release cargo when a cancer-linked enzyme cuts them, and a Shanghai team's RGD peptide gel sped wound healing in mice.

Clinical Trials

Novo's CagriSema Linked to 25% Average Weight Loss in Women in Post Hoc REDEFINE 1 Analysis, Ahead of an FDA Decision This Quarter

Novo Nordisk presented post hoc analyses of its Phase 3 REDEFINE 1 trial at The Menopause Society's annual meeting on October 20, 2026, Reuters reported: among 2,309 women with obesity or overweight, CagriSema 2.4 mg/2.4 mg was linked to 25% average weight loss at 68 weeks versus 3% on placebo, compared with 22.7% across the full trial of more than 3,400 adults. In 1,902 women grouped by menopause stage, average loss was 26.7% before menopause, 24.8% during perimenopause, and 23.1% after. Novo called the analyses hypothesis-generating; an FDA decision on CagriSema for weight management is expected in the fourth quarter of 2026.

#cagrisema #novo-nordisk #menopause #amylin
Regulatory

Sen. Jim Banks Leads Senators Urging FDA to Close the 'Research Use Only' Loophole Used to Sell Retatrutide, Citing a 265% Rise in Poisonings

Sen. Jim Banks (R-Ind.) led a group of senators in an October 14, 2026 letter, released October 15, to Acting FDA Commissioner Diamantas asking the agency to work more closely with U.S. Customs and Border Protection against vendors that sell unapproved drugs, including knockoff retatrutide, labeled "for research use only." The letter cites America's Poison Centers data showing a 265% increase in poisonings related to illicit retatrutide in the first four months of 2026 compared with the last four months of 2025, and asks for an FDA briefing on enforcement; STAT reported on October 20 that the push is bipartisan.

#retatrutide #gray-market #fda #peptide-regulation
Research

Starting Semaglutide at High Doses Was Tied to 25% Higher Risk of Early Discontinuation in 48,658 U.S. Adults

University of Texas Medical Branch researchers reported in Diabetes, Obesity and Metabolism on October 19, 2026 a MarketScan claims study of 48,658 adults with diabetes or obesity who started injectable semaglutide between 2018 and 2021. The 14.5% who began at 1.0 mg a week or more, above the labeled starting dose, had a 25% higher risk of stopping early (hazard ratio 1.25) and lower one-year persistence, independent of age, obesity status, other illnesses, and cost. High-dose starts were more common among endocrinologists, men, younger patients, and in the West and South.

#semaglutide #discontinuation #dose-titration #real-world-evidence
Research

Meta-Analysis Finds No Clear Change in Grip Strength on Semaglutide, but Evidence Is Very Weak

Researchers at the Federal University of Santa Catarina in Brazil reported in Diabetes, Obesity and Metabolism on October 19, 2026 a systematic review of 11 studies measuring muscle strength in adults on semaglutide. Pooling 10 studies with 660 participants, the average change in handgrip strength was -0.16 kgf, not statistically significant, with very large differences between studies and very low certainty of evidence. The authors said current data cannot show whether semaglutide changes muscle strength.

#semaglutide #muscle-preservation
Research

Singapore Team Designs Peptide Droplets That Release Cargo When a Cancer-Linked Enzyme Cuts Them

Researchers at Nanyang Technological University reported in ACS Nano on October 20, 2026 that peptides which separate into liquid droplets, called coacervates, can carry cargo into cells and release it when cathepsin B, an enzyme often overactive in cancer cells, cuts them. Standard cathepsin B cut sites borrowed from drug linkers worked poorly inside the dense droplets, but a newly designed four-amino-acid motif, FRFV, was cut efficiently and released cargo in cancer cells. The work is in the lab.

#drug-delivery #peptide-coacervates #cancer #preclinical
Research

RGD Peptide Hydrogel With Hyaluronic Acid Closed 96% of Skin Wounds by Day 14 in Mice, Versus 80% for the Base Gel

Researchers at Shanghai Ocean University reported in Molecules on October 19, 2026 that a carboxymethyl chitosan gel combined with hyaluronic acid and RGD, a short cell-adhesion peptide, curbed bacterial growth, reduced bleeding, and sped healing of full-thickness skin wounds in mice. Wound closure reached 95.56% by day 14 compared with 79.85% for the base gel, with denser collagen and lower inflammatory signals. The results are from mice.

#wound-healing #peptide-hydrogel #preclinical

Related Guides